NCT03480256Unknown1 期
Phase Id Trial to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Advanced Stage Gastric Carcinoma
Peking University2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2018年7月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Maximum Tolerated Dose (MTD)
研究概览
简要总结
The aim of the study is to assess the safety and tolerability of SHR6390 combined with pyrotinib in the patients with Her-2 positive advanced gastric cancer.
研究设计
- 研究类型
- Interventional
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients definitely diagnosed by pathology as Her2 positive stage III/IV gastric cancer
- •18-75 years old, ECOG PS:0-1,Life expectancy of more than12 weeks;
- •Patients treated with systematic treatment to metastatic disease then experienced progressive disease
- •Patients with at least one evaluable or measurable disease per RECIST v1.1
- •Main organs function is normal;
- •Patients should be voluntary and sign the informed consent before taking part in the study;
排除标准
- •• Patients who have uncontrollable effusion with clinical symptoms such as severe pleural effusion and peritoneal effusion;
- •A variety of factors that affect oral medication (such as inability to swallow, gastrointestinal resection, chronic diarrhea, intestinal obstruction, etc.)
- •Patients who have steroid treatment for more than 30 days or need long-term steroid treatment;
- •Patients who had previously received chemotherapy，radiotherapy, hormonotherapy,surgery,targeted therapy(including Trastuzumab) within 2 weeks ;patients who had previously received nitrosourea or Mitomycin with 6 weeks;
- •Previous treatment-related adverse events did not recover to less than 2 levels except hair loss or other conditions that did not affect the enrollment according to investigators;
- •Patients who have participated in other anticancer drug clinical trials within 4 weeks except that trial is observational or at follow up stage;
- •Patients who have uncontrollable hypomagnesemia or hypokalemia;
- •Patients with untreated or symptomatic brain metastasis;
- •Patients with malignant tumors within 5 years, except for basal cell carcinoma,squamous skin cancer and cervical carcinoma in situ;
- •Patients who are being treated with any other anticancer strategies;
- •Patients with allergic constitution or being allergic to any element in the study drugs;
- •Patients with definite gastrointestinal bleeding tendency, including: active ulcer lesions with OB(++);melena or haematemesis history within 2 months; patients with OB(+) but without tumor resection need gastroscopy. If there is active bleeding, it's not suitable for this trial;
- •Patients with active infection, including tuberculosis;
- •Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history;
- •Patients who have had severe cardiac disease within six months, including acute coronary syndrome, arrhythmias that require medication or with clinical significance, or need continuous medication that may cause QT extension, acute myocardial infarction,heart failure,and any other condition that is not suitable for this experiment according to the investigators;
- •Patients who are pregnant or breast feeding;
- •Patients who don't agree on contraception; Patients with concomitant diseases which could seriously endanger themselves or those who won't complete the study according to investigators such as hypertension, severe diabetes and thyroid diseases;
- •Patients with bad addiction such as excessive drinking or smoking;
- •Patients with definite mental disorder, including epilepsy and dementia.
研究组 & 干预措施
SHR6390 combined with pyrotinib
Experimental
Group A:pyrotinib 400mg qd combined with SHR 6390 100mg qd Group B: pyrotinib 400mg qd combined with SHR 6390 125mg qd Group C: pyrotinib 400mg qd combined with SHR 6390 150mg qd Group D: pyrotinib 400mg qd combined with SHR 6390 175mg qd Group E: pyrotinib 320mg qd combined with SHR 6390 100mg qd
干预措施: SHR6390 (Drug)
结局指标
主要结局
Maximum Tolerated Dose (MTD)
时间窗: 42 days
次要结局
- Area Under the Curve(42 days)
- Maximum Plasma Concentration(42 days)
研究者
Shen Lin
Head of Department of Gastrointestinal Oncology,Peking University Cancer Hospital
Peking University
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerAdvanced Breast CancerNCT03481998Jiangsu HengRui Medicine Co., Ltd.104
Unknown
3 期
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerAdvanced Breast CancerNCT03927456Jiangsu HengRui Medicine Co., Ltd.357
Unknown
2 期
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.HER2-positive Breast CancerER-positive Breast CancerBreast CancerNCT04236310Ruijin Hospital37
Unknown
3 期
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast CancerAdvanced Breast CancerNCT03966898Jiangsu HengRui Medicine Co., Ltd.426
尚未招募
2 期
SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic CancerPancreatic CancerNCT05185869Ruijin Hospital58